Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Community Corner
  • Published:

A delicate balance: tweaking IL-2 immunotherapy

Nature Medicine volume 18, pages 208–209 (2012)Cite this article

Subjects

William J Murphy

It is said there is nothing either good or bad but that thinking makes it so. This seems to be the case in immunology, where the role of the cytokine IL-2 has come full circle with regard to its therapeutic applications. IL-2 was initially described as a T cell growth factor and heralded as a means to augment immune responses in cancer. However, although high doses of this cytokine induce modest antitumor responses, they can also cause substantial toxicities3.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055–2066 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Saadoun, D. et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067–2077 (2011).

    Article  CAS  PubMed  Google Scholar 

  3. Atkins, M.B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).

    Article  CAS  PubMed  Google Scholar 

  4. Shin, H.J. et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 118, 2342–2350 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Willenbacher, W. et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br. J. Haematol. 112, 820–823 (2001).

    Article  CAS  PubMed  Google Scholar 

  6. Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775–787 (2008).

    Article  CAS  PubMed  Google Scholar 

  7. Malek, T.R. & Castro, I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33, 153–165 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rosenberg, S.A. & Lotze, M.T. Cancer immunotherapy using interleukin-2 and interleukin-2–activated lymphocytes. Annu. Rev. Immunol. 4, 681–709 (1986).

    Article  CAS  PubMed  Google Scholar 

  9. Yu, A., Zhu, L., Altman, N.H. & Malek, T.R. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30, 204–217 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Webster, K.E. et al. In vivo expansion of Treg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206, 751–760 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

A delicate balance: tweaking IL-2 immunotherapy. Nat Med 18, 208–209 (2012). https://doi.org/10.1038/nm0212-208

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0212-208

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing